We studied the link between T-cell activation, differentiation and senescence phenotypes and non-AIDS-related comorbidities in HIV-suppressed patients.
Introduction
The widespread introduction of combination antiretroviral therapy (cART) has improved the virological and immunological outcomes, whereas overall mortality of HIV-infected patients has been dramatically reduced [1, 2] . AIDS-related illnesses are no longer the primary causes of death, but a new set of non-AIDS-related comorbidities has emerged including cardiovascular disease, kidney disease, malignancy, as well as neurological and bone disorders, resulting in a novel systemic chronic disease [3, 4] .
Immune dysfunction, inflammation, and coagulation abnormalities persist and strongly predict risk of non-AIDS morbidity [5, 6] , even in successfully treated patients with restored peripheral CD4 þ T-cell count and complete or near-complete suppression of HIV replication [7] [8] [9] . However, reasons for immune activation in long-term HIV-RNA-suppressed patients remain yet to be fully understood [3, 10] . Comorbidities referred to as non-AIDS-related comorbidities are typically those associated with ageing in the general population, suggesting that HIV-infected individuals might suffer from accelerated ageing as they are found at a younger age in HIV-infected individuals [11] [12] [13] . Cardiovascular risk factors and direct toxic effects of antiretroviral drugs contribute, but do not fully explain, the higher risk for non-AIDS-related comorbidities [14] [15] [16] . An emerging body of evidence suggests that persistent innate and adaptative immune dysfunction and/or activation are major risk factors for non-AIDSrelated comorbidities [17, 18] . Many of the immunological abnormalities that persist during cART are similar to those observed in the elderly, raising the hypothesis that age-related decline in immune function contributes to disease progression and adverse outcomes. For example, markers of T-cell activation [human leukocyte antigen-D related (HLA-DR) and CD38 co-expression] are elevated despite effective cART and associated with subsequent morbidity and mortality, even after adjustment for CD4 þ T-cell count [8, 19] . The association of immune activation and immunosenescence with non-AIDS-related comorbidities has been widely studied in the past few years [20] [21] [22] [23] . However, one of the limits of these studies is that immune markers defining activation, differentiation, and senescence were not studied simultaneously [23] . Moreover, studies were often based on small sample sizes limiting statistical power, favoring selection, and focused on a specific non-AIDS-related comorbidity. In this cross-sectional study, we aimed at studying the link between immune activation, and immunosenescence phenotypes and non-AIDS-related comorbidities in HIV-infected patients with undetectable viral load.
Materials and methods

Study population
Patients included in the ANRS CO3 Aquitaine Cohorta prospective hospital-based cohort of HIV-1-infected patients in south-western France -were consecutively enrolled in this cross-sectional Chronic Immune Activation and Senescence (CIADIS) study between October 2011 and May 2013. The study protocol was approved by the local ethics committee, and all patients provided written informed consent. In order to avoid the bias of HIV viremia-induced activation, only patients with plasma HIV-RNA below 40 copies/ml were analyzed, irrespective of their immunological status (CD4 þ T-cell count) and hepatitis C virus (HCV)/hepatitis B virus (HBV) coinfections.
Definition of non-AIDS-related comorbidities
Comorbidities [kidney disease, diabetes, dyslipidemia, cardiovascular events, hypertension, degenerative central nervous system (CNS) disorders, and cancer] were defined using International Classification of Disease-10 codes. Renal dysfunction was estimated using the estimated glomerular filtration rate (eGFR) calculated with the simplified Modification of Diet in Renal Disease (MDRD) formula. Diabetes was defined based on hypoglycemic drug treatment use, insulin use, or two consecutive blood glucose results of at least 7 mmol/l. Dyslipidemia was defined by statin or fibrate treatment use or pathological lipid levels. Cardiovascular events were defined based on history of bypass surgery, angioplasty, or endarterectomy. Hypertension was defined based on two consecutive SBP measurements of at least 140 mmHg or DBP of at least 90 mmHg (within 2 years before inclusion).
T-cell immunophenotyping
Blood samples were analyzed centrally at the Bordeaux University Hospital Laboratory of Immunology by flow cytometry using a NAVIOS flow cytometer from Beckman-Coulter (France). All EDTA anticoagulated blood samples were analyzed fresh within a working day after blood withdrawal. A panel of 9-color markers was used with the following antibodies: FITC-CD57, PE-CD28, PC5.5-CD38, ECD-CD45RA, PC7-CD27, APC-CD4, APC Alexa 750-CD3, and APC Alexa 700-CD8 (Beckman-Coulter); V450-HLA-DR (Becton Dickinson, New Jersey, USA). Events were acquired with the CXP software and analyzed on Kaluza software. The phenotypic marker CD27 was used with CD45RA to divide CD4 þ and CD8 þ T cells into four different subsets: CD45RA þ CD27 þ [naive T cells (TN)]; CD45RA -CD27 þ [central memory T cells (TCM)]; CD45RA -CD27 -[effector memory T cells (TEM)]; and CD45RA þ CD27 -(terminally differentiated memory T cells (TEMRA)]. Activation was assessed by HLA-DR expression on CD4 þ and CD8 þ cells. Senescence on CD4 þ and CD8 þ cells was assessed by CD57 and CD28 expression (CD57 þ CD28measuring senescent T lymphocytes).
Statistical analysis
Qualitative variables were described as numbers and percentages. Quantitative variables were described as medians and IQR values. The Mann-Whitney U test was used to compare quantitative variables between groups and the chi-square or Fisher's exact test to compare qualitative variables between groups. Correlations between immune markers were calculated using the Spearman's correlation coefficient.
Principal component analysis
A principal component analysis (PCA) based on a Spearman's correlation matrix was performed on eight immune markers (percentages of activated, senescent, naïve, and terminally differentiated CD4 þ and CD8 þ T cells) in order to understand correlations between them. The main goal of PCA is to reduce the dimensionality of a dataset consisting of inter-related variables. This is achieved by transforming the original variables to a new set of variables, the principal components, which are linear combinations of the original variables and which retain most of the variation present in all original variables [24] . We used two-dimensional (2D) plots to project data on the plane spanned by the first two components which explained most variability of data (>68.7%). On this plane, the contribution of markers is unequal and depends on the contribution of each marker on each axis/principal component. A given marker may contribute on the third axis and therefore would not be well represented on the first two axes (those represented close to the origin of the figure) . Non-AIDS-related comorbidities and individual history of HIV infection were projected as supplementary variables to visualize the correlation between the components and these variables. We selected the first principal component that explained 51.5% of the variability as a continuous 'immune score' called CIADIS score throughout the study.
Main outcome variable
We counted the number of comorbidities present for each patient (comorbidity score) among: eGFR below 60 ml/min, diabetes, dyslipidemia, cardiovascular events, hypertension, degenerative CNS disorders, and cancer. We defined a high comorbidity score (at least three comorbidities) as the main outcome variable. The decision on combining comorbidities was also supported by a multiple correspondence analysis that showed an association of most of the comorbidities (dyslipidemia, hypertension, kidney function impairment, cardiovascular events, as well as diabetes) to each other ( Supplementary  Fig. 1 , http://links.lww.com/QAD/A751).
Adjustment variables
The following variables were described and tested in univariable analyses: HIV-related variables included mode of HIV transmission, last CD4 þ T-cell count, last CD4 þ /CD8 þ T-cell ratio, CD4 þ T-cell nadir, time from CD4 þ T-cell nadir, duration of CD4 þ T-cell count below 350/ml, time since first HIV-positive test, viral suppression duration, Center for Disease Control (CDC) classification, use of ART, time since the first ART, cytomegalovirus (CMV) serology status, and hepatitis B and C coinfections.
The Veterans Aging Cohort Study (VACS) index was calculated as previously described [25, 26] (Supplementary Material Tables 4a and b , http://links.lww.com/QAD/A751). This score is specifically constructed to indicate increasing risk of all-cause mortality in HIV patients with increasing score [25, 26] (Supplementary  Material Tables 5a and b , http://links.lww.com/QAD/ A751). The immune risk profile (IRP) represents a cluster of factors that were strongly predictive of earlier mortality among a very old Swedish cohort, as well as in younger individuals [27] . We calculated the IRP counting one point if the following criteria were fulfilled: CD4 þ / CD8 þ ratio less than 1, positivity of CMV serology, percentage of CD4 þ CD57 þ CD28 À above the third quartile observed in the study population (Q3), percentage of CD8 þ CD57 þ CD28 À above Q3, percentage of naive CD4 þ below the first quartile in the study population (Q1), percentage of naive CD8 þ below Q1, percentage of CD4 þ TEMRA above Q3, percentage of CD8 þ TEMRA above Q3.
Multivariable analyses
Logistic regression models were used to analyze the association between the 'CIADIS score', the VACS index, the IRP score, and having at least three comorbidities. We did separate models for each of these markers ( Table 2 , models 1, 3, and 5), and in order to test for independent association of the CIADIS score and the other scores, we included the IRP immune score and the VACS index as covariates ( Table 2 , models 2 and 4).
Furthermore, variables with a P value less than 0.25 in univariable analyses were included in a full model. Final models were obtained using a stepwise modeling procedure. Sex was maintained in the final model. All final models were adjusted for age (years), sex (female versus male), AIDS stage (stage C and B versus stage A).
We further did separate analyses for patients younger than 60 years and those aged at least 60 years, and tested whether the association between the CIADIS score, IRP, and VACS score, and having at least three comorbidities, was modified by age. We also performed sensitivity analysis including patients with detectable HIV viral load. The discriminative power of the model was assessed with the area under the receiver operator curve and the fit was assessed with a Hosmer and Lemeshow approach.
Analyses were performed using SAS 9.3 (SAS Institute, Inc., Cary, North Carolina, USA) and the free software R 3.0.0 using the R package 'FactoMineR 1.25'.
Results
Of the 3500 patients routinely followed in the ANRS CO3 Aquitaine Cohort, 1010 patients were consecutively included in the CIADIS study, of whom 876 (86.7%) patients had an undetectable viral load and were analyzed. Their baseline characteristics are summarized in Table 1 . Among them, 73.4% were men with a median age of 50.5 years (IQR 44.7-56.7 years). Median CD4 þ T-cell count was 579 cells/ml (IQR 429-759 cells/ml), median CD4 þ /CD8 þ ratio was 0.9 (IQR 0.6-1.2), 61.4% of patients had a CD4 þ /CD8 þ ratio below 1, 99.4% of patients were under cART, and median duration of HIV viral suppression was of 5.3 years (IQR 2.3-8.7). HCV coinfection was noted in 23.5% of patients and 89.4% of patients had a positive CMV serology.
Median percentages of naive T cells among CD4 þ and CD8 þ T cells were, respectively, 40% (IQR 28-51) and 38% (IQR 29-48), whereas terminally differentiated memory T cells represented 26% (IQR 16-36) among CD8 þ T cells and only 1% (IQR 0-3) among CD4 þ T cells. CD8 þ T cells were more activated and senescent compared to CD4 þ T cells (P < 0.0001) ( Supplementary  Material Table 1a , http://links.lww.com/QAD/A751). Activated CD4 þ and CD8 þ T cells expressing HLA-DR þ were positively correlated (Spearman's rank correlation coefficient r ¼ 0.63, P < 0.0001) and were also positively correlated to T CD57 þ CD28senescent T cells, as well as TEMRA subsets (P < 0.0001) (Supplementary Material Table 1b, http://links.lww. com/QAD/A751).
The first two principal components accounted for 68.7% of the variability among immunological markers (Fig. 1a ). The first principal component, accounting for 51% of the marker variability, separated naive T cells (CD45RA þ CD27 þ ) from activated T cells (HLA-DR þ on CD4 þ and CD8 þ grouped together), as well as senescent T cells (CD4 þ and CD8 þ CD57 þ CD28and CD4 þ and CD8 þ CD27 -CD45RA þ terminally differentiated T cells grouped together). The second principal component, accounting for 17% of the variability, opposed 2102 AIDS 2015, Vol 29 No 16 CD4 þ and CD8 þ T cells expressing HLA-DR to senescent CD4 þ and CD8 þ T cells (CD4 þ and CD8 þ CD57 þ CD28 À and CD4 þ and CD8 þ CD27 À CD45RA þ terminally differentiated T cells grouped together).
Comorbidities were also projected onto the plan spanned by the first two principal components (Fig. 1b ) that needs to be read in conjunction with Fig. 1a . Patients with comorbidities are found on the right side and thus were more often found in patients presenting an immune phenotype with high T-cell activation, high expression of terminal differentiation, and senescence markers.
Quantitative variables related to HIV (CD4 þ T-cell nadir, last CD4 þ T-cell count, CD4 þ T-cell count at treatment start, duration of CD4 þ T cell <350 cells/ml, duration of infection, duration of cART) were mostly located at the center of the circle and were not associated with activation or senescence phenotypes (Fig. 2a ). The projection of qualitative HIV and non-HIV-related variables onto the plan spanned by the first two components are represented on Fig. 2b that needs to be read in conjunction with Fig. 2a . These variables were not associated with a particular T-cell phenotype in most of the cases. HCV coinfection, plotted on the left bottom corner, was not associated with either T-cell activation or senescence.
The distribution of comorbidities is represented in Table 1 . Dyslipidemia and hypertension were the most frequent comorbidities accounting for 36.2 and 35.4% of patients, respectively. Severe kidney function impairment (eGFR <60 ml/min) and CNS degenerative disorders only concerned, respectively, 3.5 and 2.9% of patients. Also, 37.4% of patients had no comorbidity and 13.6% of patients suffered from at least three comorbidities.
In univariable analysis, we found that an older age, sex (male), and AIDS stage were associated with at least three comorbidities (respectively, P < 0.0001, P ¼ 0.0014, P < 0.0001). Last CD4 þ T-cell count or HCV coinfection was not associated with a high number of comorbidities. Patients with a higher CD4 þ nadir had a lower risk for presenting at least three comorbidities ( Supplementary Material Table 2 , http://links.lww.com/ QAD/A751). Higher CD4 þ and CD8 þ T-cell activation were significantly associated with the presence of at least three comorbidities (respectively, P ¼ 0.0004, P ¼ 0.0001). Higher percentage of senescent and terminally differentiated T cells, and lower percentage of naïve T cells were also significantly correlated with a high comorbidity score (Supplementary Material Table 3 , http://links.lww.com/QAD/A751).
Variables used for the calculation of the VACS index and the IRP score are summarized in Supplementary Material Tables 4 and 5 (http://links.lww.com/QAD/A751), respectively. Among the patients included in the CIADIS study, 14.2% had a VACS index at least 35 and 50.3% had a high IRP (!3). A high VACS index as well as a high IRP score were significantly associated with a high number of comorbidities in our study (respectively, P < 0.0001, P ¼ 0.0006). Furthermore, the CIADIS score was also significantly associated with the presence of at least three comorbidities (P < 0.0001) (Supplementary Material Table 3 , http://links.lww.com/QAD/ A751).
In multivariable analysis (Table 2) , after adjustment for age, sex, and AIDS stage, a higher CIADIS score was significantly associated with the presence of at least three comorbidities [model 1: odds ratio (OR) 1.3, 95% confidence interval (CI) 1.0-1.7, P ¼ 0.02] and was also significantly associated after additional adjustment with the VACS index (model 2: OR 1.3, 95% CI 1.0-1.6, P ¼ 0.02). However, the discriminant power measured by 2104 AIDS 2015, Vol 29 No 16 Table 2 . Factors associated with the presence of at least three comorbidities adjusted for HIV-related characteristics (multivariable analysis). AUROC increased little for the model including the CIADIS score (AUROC ¼ 0.787) compared to a model without the CIADIS score (AUROC ¼ 0.782), respectively.
Neither the VACS index (model 5: OR 1.2, 95% CI 0.7-2.1, P ¼ 0.59) nor the IRP score (model 3: OR 1.5, 95% CI 0.9-2.5, P ¼ 0.09) was statistically associated with the presence of at least three comorbidities. An older age as well as B and C AIDS stages were associated with a high comorbidity score, irrespective of the adjustment model. As comorbidities might occur in younger ages in HIV patients compared to the general population, we did separate analysis in younger patients (<60 years old) versus older patients (!60 years old) ( Table 3 ). We found that the CIADIS score as well as IRP were significantly associated with a high comorbidity score in younger patients (OR 1.4, 95% CI 1.1-1.9, P ¼ 0.02; and OR 1.8, 95% CI 1.0-4.4, P ¼ 0.047, respectively). The VACS index was significantly associated in the model including the IRP and CIADIS scores only (Table 3 ). We did not find any significant association between the CIADIS score, the VACS index, or the IRP score with a high comorbidity score in patients older than 60 years. However, there was no statistically significant interaction between age and the different scores (P ¼ 0.57, P ¼ 0.63; P ¼ 0.21, respectively). In sensitivity analyses including patients with detectable viral load (n ¼ 1010), we found similar results regarding the association between the CIADIS score and comorbidities (data not shown).
Discussion
In a large assessment of T-cell activation markers in patients under routine care, we found a significant association between the CIADIS score and a high comorbidity score, whereas the VACS index as well as the IRP score were not associated with a high comorbidity score in multivariable analysis.
Our results are in contrast with the recently published data from the study by Tenorio et al. [23] where T-cell activation was not significantly related to the occurrence of non-AIDS-defining events. In this study, all comorbidities usually associated to HIV infection were not studied simultaneously. Immune activation was assessed 1 year after cART initiation and at the time-point immediately preceding the event, which occurred at a median of 2.9 years after initiation. The different findings might be explained by the differences in patients' characteristics as in our study population, the median duration since diagnosis was 17.3 years, with a median duration of viral load suppression of 5.8 years in patients under cART since a median of 14.1 years. In a recent study by Guaraldi et al. [28] , duration since diagnosis was a major factor associated with comorbidities. Even after AIC, Akaike information criterion; AUROC, area under the receiver operator curve; CI, confidence intervals; CIADIS, Chronic Immune Activation and Senescence; IRP, immune risk profile; OR, odds ratio. Note 1: P value of the interaction between age and CIADIS score was not significantly adjusted for VACS index score, age, sex, and AIDS stage (P ¼ 0.5740). Note 2: P value of the interaction between age and IRP score was not significantly adjusted for VACS index score, age, sex, and AIDS stage (P ¼ 0.2146). Note 3: P value of the interaction between age and VACS index score was not significantly adjusted for age, sex, and AIDS stage (P ¼ 0.6289).
a Odds-ratio given for a one standard deviation (SD) increase (SD of CIADIS score: 2.0).
adjustment for duration since HIV diagnosis, we confirmed a statistically signification association between the CIADIS score and the presence of more than two comorbidities (Supplementary Material Table 6 , http:// links.lww.com/QAD/A751).
Evidence is accumulating that the risk of non-AIDSrelated comorbidities is elevated in HIV-positive individuals, they may be occurring at a younger age than what is typically observed among comparable HIV-negative populations [4, 29] . Guaraldi et al. [4] demonstrated that the prevalence of polypathology (defined as the concurrent presence of at least two comorbidities) in HIV-infected persons anticipated polypathology prevalence observed in the general population among persons who were 10 years older. These data call for an earlier screening of noninfectious comorbidities in HIV-infected patients. Among a broad array of factors that may be contributing to the emergence of comorbidities at younger ages in the HIV population, HIV-specific cofactors have been already described [30] . However, HIV-related characteristics do not fully explain the occurrence of comorbidities that could also be linked to immune dysfunctions that persist even after long-term viral suppression and CD4 þ reconstitution, especially T-cell activation [31, 32] . To study immune activation and immunosenescence, we used a PCA approach to evaluate the association of activation (as measured by the percentage of HLA-DR þ T cells among CD4 þ and CD8 þ cells), senescence (as measured by the percentage of CD57 þ CD28cells among CD4 þ and CD8 þ cells), and differentiation (with a focus on naive and terminally differentiated CD4 þ and CD8 þ cells). Activation and senescence markers were inversely associated with naive markers. It led us to identify two patterns of patients: a cluster of patients characterized by high expression of activation and senescence markers and low levels of naive T cells, and a cluster of patients exhibiting high levels of naive T cells and low expression of activation and senescence markers. If cellular activation is associated with AIDS-defining outcomes in untreated and treated HIV infection [14, 18] , the impact of cellular immune activation on comorbidities is less well studied. Most of the studies on this topic examined the relationship between immune activation and morbidity before cART initiation, but do not address whether elevated immune activation after a defined and uniform period of cARTinduced viral suppression is associated with outcomes. As HCV has the ability to stimulate the adaptative immune system, it was interesting to look at the role of HCV coinfection in T-cell activation and comorbidities. In our study, we found that HCV coinfection seemed to be protective against T-cell activation and senescence. It perhaps explains why we did not find any correlation between HCV coinfection and a high score of comorbidities. These data suggest that HIV-associated T-cell activation and senescence are involved in comorbidities in suppressed HIV recipients and points to immune activation being involved in comorbidities independently of a unique cardiovascular pathway. T-cell activation in the context of HIV infection is usually assessed by HLA-DR and CD38 coexpression on CD4 þ and CD8 þ cells, whereas HLA-DR alone is regularly studied as a marker of T-cell activation in non-HIV populations, based upon the fact that CD38 is also expressed by naive T cells. In patients who achieved viral suppression, Cockerham et al. [33] found a strong association between the frequencies of CD4 þ or CD8 þ cells expressing HLA-DR and HIV-DNA levels in resting CD4 þ cells. Similar correlations were also observed when activation was defined by the percentage of CD4 þ or CD8 þ cells coexpressing CD38 and HLA-DR; however, the strength of these heavily relied on HLA-DR expression by T cells, as no correlation was observed with CD38 alone [33] . We therefore studied association between comorbidities and T-cell activation assessed by coexpression of HLA-DR and CD38, and found the same pattern of data we found with HLA-DR expression (data not shown).
As occurrence of comorbidities at younger ages has been part of the definition of accelerated and premature aging of HIV patients, we examined the putative association between a high comorbidity score and the CIADIS score separately in patients younger than 60 and those older than 60 years of age. We found that the CIADIS score, IRP score and VACS index were statistically associated with at least three comorbidities in younger patients. However, the association between the CIADIS score (and IRP) and the comorbidity score may be biased, especially in the stratum over 60 years, and underestimated due to a higher probability for older patients having died before the inclusion period in the CIADIS study.
The development and validation of a multivariable risk index for people with HIV has been a priority. The VACS has raised the challenge with the rollout of the pointsbased VACS index [26] . Because the impact of HIV infection on the immune system mirrors that of aging in many respects, IRP defined as a cluster of immunological factors that are strongly predictive of earlier mortality among a non-HIV elderly cohort should be interesting to study in the context of HIV infection. The CIADIS score was significantly associated with a high comorbidity score, especially in younger patients. However, the added discriminant power was little and an external validation of our findings should be done using a completely independent sample. Furthermore, the CIADIS crosssectional study cannot show that immune activation, as well as immunosenescence, is involved in the occurrence of non-AIDS-related comorbidities. Other markers such as soluble inflammation markers may also be relevant for predicting non-HIV-related comorbidities. Thus, future analyses using longitudinal data from patients included in the CIADIS study are planned.
In conclusion, the weighted CIADIS score based on activation, senescence, and maturation markers might be a tool to help physicians identify patients at a higher risk for non-AIDS-related comorbidities in the future.
